Kinfo
Inovio Pharmaceuticals Inc. logo

Inovio Pharmaceuticals Inc.

INONASDAQHealthcare·US · USD
$1.13
-0.02 (-1.74%)
Prices as of October 6, 2026 · market closed

Price

Key statistics

Valuation
Market cap116.84M USD
Enterprise value91.27M USD
Trailing P/E-0.62
Forward P/E-2.64
PEG ratio0.01
Price / sales1,788.09
Price / book21.89
Profitability
Gross margin0.00%
Operating margin-130000.00%
Profit margin0.00%
Return on assets-84.23%
Return on equity-409.87%
Income (TTM)
Revenue65.34K USD
Gross profit-48.49M USD
EBITDA-77.93M USD
Net income-67.43M USD
Diluted EPS-$0.90
Rev. growth (YoY)0.00%
Balance sheet
Total cash36.67M USD
Total debt8.00M USD
Debt / equity183.07
Current ratio1.00
Book value / share$0.05
Cash flow (TTM)
Operating cash flow-80.58M USD
Levered free cash flow-33.86M USD
Shares & price
Shares outstanding103.40M
Float95.79M
Held by institutions46.01%
Beta1.63
50-day MA$1.11
200-day MA$1.36
52-week high$2.72
52-week low$0.56
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-12-0.24-0.24+0.00%2026-05-13-0.33-0.31+6.06%2026-03-27-3.78-0.97+74.34%2026-03-12-0.34-0.28+17.65%2026-03-02-0.54-0.70−29.63%
About Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The company’s work centers on DNA-based immunotherapies and vaccines designed to help prevent or treat conditions such as recurrent respiratory papillomatosis, cervical dysplasia, and other virus-associated or oncology indications. Its platform combines synthetic DNA design with proprietary delivery technology to support immune-system activation across a range of therapeutic areas. Inovio’s current product pipeline reflects an emphasis on diseases linked to human papillomavirus as well as selected infectious and cancer-related programs. Based in Plymouth Meeting, Pennsylvania, Inovio Pharmaceuticals Inc. occupies a specialized position in the biotechnology market as a developer of next-generation DNA medicine technologies.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jacqueline E. Shea Ph.D.
Employees
134
Headquarters
Plymouth Meeting, PA, United States

Frequently asked questions about Inovio Pharmaceuticals Inc.